Head-To-Head Comparison: Autonomix Medical (NASDAQ:AMIX) vs. Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ:PACB) and Autonomix Medical (NASDAQ:AMIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Profitability

This table compares Pacific Biosciences of California and Autonomix Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-341.47%	-326.43%	-19.40%
Autonomix Medical	N/A	-228.82%	-186.65%

Analyst Ratings

This is a breakdown of current ratings and target prices for Pacific Biosciences of California and Autonomix Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2	2	1	0	1.80
Autonomix Medical	1	1	1	0	2.00

Pacific Biosciences of California presently has a consensus price target of $1.67, indicating a potential upside of 4.82%. Autonomix Medical has a consensus price target of $2.00, indicating a potential upside of 488.06%. Given Autonomix Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Autonomix Medical is more favorable than Pacific Biosciences of California.

Earnings & Valuation

This table compares Pacific Biosciences of California and Autonomix Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01 million	3.09	-$546.38 million	($1.84)	-0.86
Autonomix Medical	N/A	N/A	-$11.41 million	($3.55)	-0.10

Autonomix Medical has lower revenue, but higher earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Pacific Biosciences of California has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Comparatively, Autonomix Medical has a beta of -2.48, indicating that its stock price is 348% less volatile than the S&P 500.

Institutional and Insider Ownership

10.8% of Autonomix Medical shares are owned by institutional investors. 2.5% of Pacific Biosciences of California shares are owned by company insiders. Comparatively, 6.2% of Autonomix Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Autonomix Medical beats Pacific Biosciences of California on 8 of the 12 factors compared between the two stocks.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.